hero-transparent

OUR PARTNERS

img

Laronde, founded in 2017, by Flagship Labs, is building a new biotech company around their modular Endless RNA™ (eRNA) platform – a completely novel way of modulating human biology – supported by a large-scale digital and manufacturing infrastructure, with the bold vision of 100 new medicines within the next decade.

Endless RNA™ (eRNA), is a uniquely engineered RNA that can be programmed to express diverse therapeutic proteins inside the body.  It is persistent, non-immunogenic, allows for repeat dosing, and offers flexibility in formulation and delivery.

In 2021, the JIMCO Life Sciences Fund participated in Laronde’s Series B funding round to advance the development of its eRNA platform and a broad pipeline of programs across a number of therapeutic categories.

The company is rapidly scaling to support the parallel development of multiple programs across many disease areas.

Visit: Laronde